From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
insights into tumor heterogeneity, clonal evolu- tion, and mechanisms of drug resistance—critical factors in the development of next-generation diagnostics and therapeutics. Key advantages of WGS include: • Detection of all variant types across the entire genome • An unbiased, comprehensive view of both coding and noncoding regions • Utility in resistance mechanism studies, rare cancers, and discovery research Today, WGS is increasingly being implemented in specialized oncology settings, particularly for rare, refractory, or undiagnosed cancers where conven- tional panels fail to yield actionable insights 7 ( Table 3 ). It is also being applied in research-driven clinical trials and national precision medicine initia- tives to uncover novel biomarkers, track disease evolution, and guide the use of emerging targeted
therapies. In pediatric oncology and hematologic malignancies, WGS has shown promise in detecting cryptic rearrangements, and complex genomic alterations that inform prognosis and influence treatment selection. As sequencing costs continue to fall and data analysis tools become more acces- sible, WGS is expected to play an expanding role in comprehensive cancer aprofiling and personalized treatment planning. However, broader clinical adoption of WGS remains limited by several challenges. These include high sequencing costs, longer turnaround times, and the need for advanced bioinformatics infrastructure to manage and interpret the vast volume of data generated. In addition, many of the variants identified through WGS are of uncertain clinical significance, requiring expert curation, robust databases, and clinical correlation—factors that continue to complicate reporting and down- stream clinical decision-making. 8 ease of use make it ideal for detecting well-characterized, high-prevalence mutations that inform immediate treatment decisions— such as EGFR, KRAS, or BRAF status in frontline therapy selection. • tNGS follows when a broader molecular picture is required. It enables comprehensive mutation profiling, including less common variants, gene fusions and copy number alterations across dozens to hundreds of genes. This depth of information
The Power of Strategic Combinations and Integration As the complexity of cancer biology and treatment continues to grow, no single diagnostic technology can meet all clinical needs. Instead, forward-
looking oncology strategies increasingly rely on a layered, multi-platform approach—leveraging the unique strengths of qPCR, targeted NGS (tNGS), and whole-genome sequencing (WGS) at different stages of care 9 ( Table 4 ). • qPCR is typically used as a first-line tool for rapid eligibility screening. Its speed, low cost, and
16 | GENengnews.com
Powered by FlippingBook